Finally, we examined the functional significance of our newly-discovered enzalutamide-activated genes, NR3C1, SLC7A11, TSC22D3, LAMP3, VEGFA and CEMIP. Silencing of each of these genes significantly enhanced the cell growth inhibitory effect of enzalutamide (Supplementary Figure S11), suggesting that expression of these genes compromises the ability of enzalutamide to inhibit prostate cancer growth. The gene discussed is TSC22D3; the disease is Familial prostate cancer.